Table 3.

Quercetin in clinical trials for metabolic and inflammatory disorders.

Status	Study Title	Conditions	Intervention	Phase	NCT Number
Completed	Effect of Quercetin in Prevention and Treatment of Oral Mucositis	Chemotherapy Induced Oral Mucositis	250 mg daily for 3 weeks	Phase 1/2	NCT01732393
Completed with results	Beneficial Effects of Quercetin in Chronic Obstructive Pulmonary Disease (COPD)	Chronic Obstructive Pulmonary Disease	500 to 2,000 mg daily for 1 week	Phase 1	NCT01708278
Completed	Q-Trial in Patients With Hepatitis C	Chronic Hepatitis C	28 days	Phase 1	NCT01438320
Completed	Effects of Quercetin on Blood Sugar and Blood Vessel Function in Type 2 Diabetes.	Diabetes Mellitus, Type 2	250 mg; oral single dose of 2000 mg	Phase 2	NCT01839344
Completed	Effect of Quercetin Supplements on Healthy Males: a 4-Week Randomized Cross-Over Trial	Hyperuricemia, Gout, Kidney Calculi, Diabetes, Cardiovascular Disease	500 mg tablet for 28 days with meal (breakfast preferred.)	Early Phase 1	NCT01881919
Completed	Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial	Idiopathic Pulmonary Fibrosis (IPF)	3 doses administered over 3 consecutive days in 3 consecutive weeks, oral administration of quercetin (1,250 mg daily)	Phase 1	NCT02874989
Completed	Efficacy of Provex CV Supplement to Reduce Inflammation Cytokines and Blood Pressure	Blood Pressure	330 mg of Provex CV supplement, by mouth, per day, for 4 weeks	Phase 1	NCT01106170
Completed	Effects of Hesperidin on Bone Mineral Density and Bone Metabolism of Postmenopausal Women	Osteoporosis, Osteopenia		Phase 3	NCT00330096